Alvotech Announced That The Egyptian Drug Authority Has Approved The Manufacturing And Distribution Of AVT02 (Adalimumab) A Biosimilar For Humira, Indicated For Rheumatoid Arthritis And Several Other Inflammatory Diseases, Under Adalimumab-EVA Name
Portfolio Pulse from Benzinga Newsdesk
Alvotech has received approval from the Egyptian Drug Authority to manufacture and distribute AVT02 (Adalimumab), a biosimilar for Humira, under the name Adalimumab-EVA. This drug is indicated for rheumatoid arthritis and several other inflammatory diseases.
August 29, 2023 | 9:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alvotech's approval to manufacture and distribute AVT02 in Egypt could potentially increase its revenue and market share in the region.
The approval of AVT02 by the Egyptian Drug Authority allows Alvotech to manufacture and distribute the drug in Egypt. This could potentially increase Alvotech's revenue and market share in the region, as it now has a product that can be sold to a new market. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100